Not exact matches
Another research goal is to find out whether the mutation leads to
specific types of
tumours or cancers that are triggered at a particular time of life.
In recent years, researchers have discovered several ways of using genome sequencing of
tumours to predict whether an individual cancer patient will benefit from a
specific type of medicine.
«It tells you about the ecosystem of the
tumour», Simona says, «using fluorescent markers, we can label many
specific cell
types and structures within the brain in the vicinity of the
tumour, and look not just at the
tumour cells but how they interact with their surroundings.
Inclusion Criteria: • Availability of tumor tissue for mesothelin expression testing • Histologically - confirmed, mesothelin - expressing metastatic or advanced non-metastatic disease (
tumour type specific inclusion criteria) • At least one measurable lesion according to either Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 or International Thymic Malignancy Interest Group (ITMIG) modified RECIST 1.1 as applicable • Adequate bone marrow, liver, renal and coagulation function • Left ventricular ejection fraction (LVEF) ≥ 50 % of the lower limit of normal (LLN) according to local institutional ranges • Eastern Cooperative Oncology Group (ECOG) 0 or 1 Exclusion Criteria: • More than one prior anti - tubulin / microtubule agent • Corneal epitheliopathy or any eye disorder that may predispose the patients to this condition • Symptomatic Central nervous system (CNS) metastases and / or carcinomatous meningitis • Contraindication to both CT and MRI contrast agents • Active hepatitis B or C infection • Pregnant or breast - feeding patients • Tumor
type specific exclusion criteria
The program works by looking for
specific molecular patterns in cancer DNA that is free flowing in the patients» blood and comparing the patterns against a database of
tumour epigenetics, from different cancer
types, collated by the authors.